TLR9 and melanoma: PF-3512676, one of the earlier synthetic TLR9 agonists to treat melanoma patients, increases pDC and mDC frequency, along with the release of inflammatory cytokines, while markedly reducing Treg cell population in the sentinel lymph nodes (SLN) (138).